Dual-PCR Target HIV-1 Test Amplifies and Detects Two Separate Regions of Target Genome

The first dual-polymerase chain reaction (PCR) target viral-load test has been approved in the United States for monitoring HIV patients receiving antiretroviral therapy.

Roche Molecular Diagnostics (Basel, Switzerland) announced today that the Food and Drug Administration (FDA) approved its new dual-PCR target HIV-1 viral-load test to quantify the amount of virus in a patient's blood. The Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, v2.0 is the first quantitative viral-load test to amplify and detect two separate regions of a target genome and offers a fully automated and effective solution for physicians to make informed treatment decisions for HIV-1 patients undergoing antiretroviral therapy.

"With the introduction of this test, Roche is the only company in the world to offer a dual-PCR target quantitative viral load assay,” said Paul Brown, president and CEO of Roche Molecular Diagnostics. "By virtue of its design, the Cobas AmpliPrep/Cobas TaqMan HIV-1 Test, v2.0 can improve the ability of physicians and laboratories to obtain reliable information about HIV-infected patients in order to make informed treatment decisions.”

Highly active antiretroviral treatment (HAART) and viral-load tests, which are used to monitor the amount of human immunodeficiency virus (HIV) circulating in blood, have contributed to a 13-year increase in life expectancy for people infected with HIV. According to the World Health Organization (Geneva, Switzerland), 33 million people were living with HIV at the end of 2008. That same year, some 2.7 million people became newly infected, and 2.0 million died of AIDS, including 280,000 children. Roche is focused on expanding access to laboratory testing in resource-limited settings via its humanitarian programs.

"Treatment of HIV patients with new antiviral therapies, such as integrase inhibitors, has met with success, but can also introduce selective pressures that result in changes to the HIV genome, which could make it harder to detect and treat,” said Tri Do, M.D., director for clinical research and scientific affairs, Roche Molecular Diagnostics, and an HIV-treating physician. "Roche's new dual-PCR target HIV-1 viral load test is designed to detect current and emerging genomic variants of HIV with increased sensitivity.”

The test delivers a wide dynamic range of detection, with the ability to detect HIV-1 RNA (group M and O) down to 20 copies per milliliter in EDTA (ethylenediaminetetraacetic acid) plasma. The test is fully automated on the Cobas AmpliPrep/Cobas TaqMan system, which is in use by over 250 laboratories in the United States for clinical viral load testing. For improved laboratory workflow efficiency and rapid turnaround time of results to clinicians, the new HIV-1 viral load test may be run in parallel with Hepatitis C viral load testing on the same system.

This test is intended for use in conjunction with clinical presentation and other laboratory markers of disease progress for the clinical management of HIV-1 infected patients. The test can be used to assess patient prognosis by measuring the baseline HIV-1 RNA level or to monitor the effects of antiretroviral therapy by measuring changes in EDTA plasma HIV-1 RNA levels during the course of antiretroviral treatment.

Roche is the world's largest biotech company with differentiated medicines in oncology, virology, inflammation, metabolism, and central nervous system (CNS).

Related Links:
Roche Molecular Diagnostics